ATLANTA, July 24, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) today announced that Russell H. Plumb, its President and Chief Executive Officer, and other Company executives will present an update on the Company and its key programs for shareholders and other interested parties on the following dates:
-
Tuesday, 30 July 2013 in Melbourne at The InterContinental Melbourne The Rialto
495 Collins Street, Melbourne, Victoria, Australia - Wheat Room on Lower Ground Floor
-
Thursday, 01 August 2013 in Sydney at The Grace Hotel
77 York Street, Sydney, NSW Australia – Marra Room on Level Two
The briefings will commence at 11:00am AEST and will run for approximately one hour.
About Biota
Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The Company currently has two Phase 2 clinical-stage product candidates in development: Laninamivir octanoate, which the Company is developing for the treatment of influenza A and B infections in the U.S. through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that provides up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad-spectrum capsid inhibitor of enteroviruses, including human rhinovirus. In addition to these clinical-stage programs, the Company has preclinical programs focused on developing treatments for respiratory syncytial virus and gram-negative, multi-drug resistant bacterial infections. For additional information about the Company, please visit www.biotapharma.com.